Physician profile
Joseph Andrew Manfredi
NPI 1053362269
$212,700.51
in general payments reported to CMS, 2019-2025
24 companies · $2,199 in 2025
The $2,199 reported for 2025 was less than what a typical Clinical Cardiac Electrophysiology provider received nationally (typical 2025 total: $2,477).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $42K · 2020: $13K · 2021: $45K · 2022: $61K · 2023: $31K · 2024: $19K · 2025: $2,199.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $23K · Consulting Fee: $19K · Food and Beverage: $10K · Travel and Lodging: $245.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $23,165.00 |
| Consulting Fee | $18,506.25 |
| Food and Beverage | $10,299.95 |
| Travel and Lodging | $244.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $114,412.79 | 2019-2025 | Advisor, Ensite, Gallant |
| Janssen Pharmaceuticals, INC | $93,382.14 | 2019-2024 | Xarelto |
| Atricure, INC. | $1,316.12 | 2019-2025 | Epi-Sense Guided Coagulation System With Visitrax |
| Philips North America LLC | $1,000.62 | 2020-2025 | (Ck4) Mcot, Ecc Solutions, (Am5) Lead Management |
| Medtronic, INC. | $604.57 | 2022-2025 | Onyx Frontier, Symplicity G3, Azure Xt Dr Mri Surescan |
| Janssen Scientific Affairs, LLC | $355.08 | 2021-2023 | Xarelto |
| Boston Scientific Corporation | $328.24 | 2020-2025 | Watchman, Watchman Flx, General - Brady |
| Biotronik INC. | $279.53 | 2019-2022 | |
| Cardiva Medical, INC. | $256.20 | 2019-2025 | Cardiva Vascade Mvp Vvcs 6-12f, Cardiva Vascade 6/7f Vcs |
| Biosense Webster, INC. | $241.64 | 2019-2024 | Carto 3 |
| Impulse Dynamics (USA) INC. | $178.25 | 2023 | Optimizer |
| Astrazeneca Pharmaceuticals Lp | $57.15 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $50.98 | 2023 | |
| Infobionic, INC | $31.87 | 2020 | |
| Medtronic Vascular, INC. | $30.21 | 2019-2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $27.70 | 2025 | Mako |
| Innovation Technologies INC | $25.66 | 2022 | |
| Shockwave Medical, INC | $24.67 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Kiniksa Pharmaceuticals, Ltd. | $21.48 | 2023 | Arcalyst |
| Novo Nordisk INC | $21.41 | 2025 | Wegovy |
| Kestra Medical Technology Services, INC. | $21.30 | 2024 | Assure Wcd |
| Pfizer INC. | $14.99 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $12.91 | 2022 | |
| Bardy Diagnostics, INC. | $5.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Manfredi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.